Naronapride is under clinical development by Renexxion and currently in Phase II for Diabetic Gastroparesis. According to GlobalData, Phase II drugs for Diabetic Gastroparesis have an 18% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Naronapride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Naronapride overview

Naronapride is under development for the treatment of multiple gastrointestinal disorders including chronic idiopathic constipation, irritable bowel syndrome-constipation (IBS-C), diabetic gastroparesis, functional dyspepsia and gastrointestinal dysmotility. The drug candidate is administered through oral route in the form of tablet. It acts by targeting serotonin type 4 (5HT4) and dopamine-2 receptor (D2). The drug candidate is designed based on Retrometabolic drug design technology. It was also under development for gastroesophageal reflux disease (GERD).

Renexxion overview

Renexxion, LLC, a pharmaceutical company, develops oral 5HT4 agonist for gastrointestinal (GI) disorders. The company is headquartered in United States.

For a complete picture of Naronapride’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.